Title |
Rho kinase inhibitors for glaucoma treatment - Review
|
---|---|
Published in |
Arquivos Brasileiros de Oftalmologia, January 2015
|
DOI | 10.5935/0004-2749.20150103 |
Pubmed ID | |
Authors |
Renato Antunes Schiave Germano, Simone Finzi, Pratap Challa, Remo Susanna |
Abstract |
Glaucoma is a progressive optic neuropathy characterized by the loss of ganglion cells and their axons. A major risk factor for glaucomatous visual field loss is elevated intraocular pressure (IOP), and several studies have shown that lowering IOP reduces the risk of glaucomatous progression. Currently, an increasing number of researches involve Rho kinase inhibitors, which are a new pharmacological class of hypotensive agents specifically targeting the diseased trabecular outflow pathway. Rho kinase inhibitors reduce IOP by increasing aqueous humor drainage through the primary outflow pathway in the eye, which is known as the trabecular meshwork. In addition to improving the outflow facility of the trabecular meshwork, Rho kinase inhibitors also enhance retinal ganglion cell survival after ischemic injury and increase ocular blood flow. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 31 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 4 | 13% |
Student > Ph. D. Student | 4 | 13% |
Student > Doctoral Student | 3 | 10% |
Researcher | 3 | 10% |
Other | 2 | 6% |
Other | 3 | 10% |
Unknown | 12 | 39% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 16% |
Medicine and Dentistry | 4 | 13% |
Biochemistry, Genetics and Molecular Biology | 3 | 10% |
Agricultural and Biological Sciences | 2 | 6% |
Neuroscience | 2 | 6% |
Other | 3 | 10% |
Unknown | 12 | 39% |